Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. - Wikidata - wikimedia - TriplyDB

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

http://www.wikidata.org/entity/Q34277031

about

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease Highlights of the year in JACC 2012 Hemoglobin α in the blood vessel wall Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer Prevention of PKG1α oxidation augments cardioprotection in the stressed heart.Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.RNA-Seq Analysis of Abdominal Fat in Genetically Fat and Lean Chickens Highlights a Divergence in Expression of Genes Controlling Adiposity, Hemostasis, and Lipid Metabolism The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.An Update on Intradialytic Cardiac Dysfunction.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Iα.Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.Tadalafil prevents acute heart failure with reduced ejection fraction in mice.Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an L-NAME model of pre-eclampsia.

P2860

Q24323316-5ABE5DA0-81AD-453C-8421-C47F45ECA1DE Q26865608-0609A127-DC03-4221-A4F0-F7848A7A455E Q30371614-E9FD7814-6718-4C81-A960-CBECD661B7F6 Q31146253-07EF34D2-1F9C-4800-B3A0-7955F73B99B4 Q34634339-C81AF1A3-A8A9-42E0-A95A-E9A659030E1A Q35057768-C64AEAAC-3BFB-4E01-83BB-81656C08EFA7 Q35827798-25C6C490-E519-4831-8E73-6D0F88F4397E Q35836147-2A3C0777-09BD-460C-8AB5-7BFB998F37E9 Q36128551-FA4EF216-7FE2-482A-A1D0-A3BF58AD67EE Q36133131-FEADFEDB-CF3E-4A54-99D0-57CA59BAB63B Q36234790-A40FF6AA-4F5A-45D5-8083-D7FFD4EEA2B7 Q37648508-7B253709-F6C5-4820-AAA6-53234846F72C Q38807482-475849BF-C544-410D-823D-395E251D0BE1 Q39141728-33D861B2-E0A8-40BB-89E3-F039A61C509C Q41189484-1FCFA643-8F8D-4E1F-A04C-EA18529AB162 Q44338340-316C03CA-F59B-4BA0-9BA0-D518590CF0B4 Q45004611-37986B17-86F7-4C26-A25E-168B284BFA04 Q45053546-505604AD-ABD6-4245-8B37-7B7C8F7BC49C Q51249136-43BB0D03-526E-47B9-B488-931660ED65D4

P2860

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

http://www.wikidata.org/entity/Q34277031

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@ast

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@en

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@nl

type

label

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@ast

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@en

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@nl

prefLabel

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@ast

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@en

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@nl

P1433

Q34277031-883E7555-C458-4FF0-80CA-B448551CCA70

P1476

Q34277031-92C6047A-E694-4FEE-A9E5-C4A383D87528

P2093

Q34277031-034B0415-5E72-4558-8154-C812202FCC3C

Q34277031-4166C9AA-C062-42A3-8147-624A6C1EF089

Q34277031-4C52AC0C-58CB-4704-B7F9-A9D11BA634AB

P2860

Q34277031-0AAB9B40-72A3-41AA-B235-41D845EA294E

Q34277031-0C6C6415-AA6D-4E1D-BBD5-DCBBBF5A63A1

Q34277031-0FC56B60-5D83-455E-AB33-56FB7E8943B8

Q34277031-1991F943-C44F-4140-BA8E-33EBA6C44F00

Q34277031-1D96E52C-EA2E-48E3-9755-074C75D04B9D

Q34277031-2FFFF427-F8EA-48D9-B114-C5FE7DAABEB1

Q34277031-325F4BF5-12A8-4023-A9E7-D403403EA229

Q34277031-3923871B-A923-4D30-BDB9-521BAC8BE31C

Q34277031-49ABBF95-EF3D-4005-979C-B708A7DBE09A

Q34277031-4FF234BE-9969-4143-BD1A-05BBA199B695

P304

Q34277031-DA5B626F-BBDE-4471-8EC2-8CF7C6EDD19A

P31

Q34277031-8B338C5F-A851-4AAB-898E-7AE35CE5AAF1

P356

Q34277031-3835A5B7-90A4-4DD1-808A-29F41AA22E75

P407

Q34277031-26401B8B-816C-46D9-8691-4FFC5DA5FA95

P433

Q34277031-BDB10F8F-F26F-4AEC-9243-C3867BE0C45E

P478

Q34277031-E9289E97-1805-4966-86E2-3B5B33CE151D

P577

Q34277031-A7E30E34-5A64-4BC0-981A-556BCCFCCA39

P5875

Q34277031-06B06386-AAC4-420A-A785-77FA02DD4191

P698

Q34277031-D05C7505-A726-46D9-B1ED-8C3CB38BE24A

P932

Q34277031-C19DAA7F-F936-4E65-89E4-24858A3BAD08

P356

J.JACC.2011.09.086

P1433

Journal of the American College of Cardiology

P1476

Cyclic guanosine monophosphate ...... nhibitors in cardioprotection.

@en

P2093

Anindita Das

http://www.w3.org/2001/XMLSchema#string

Fadi N Salloum

http://www.w3.org/2001/XMLSchema#string

Rakesh C Kukreja

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Dwarfism and early death in mice lacking C-type natriuretic peptide

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition

P304

1921-1927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2011.09.086

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225042974

http://www.w3.org/2001/XMLSchema#string

P698

22624832

http://www.w3.org/2001/XMLSchema#string

P932

4230443

http://www.w3.org/2001/XMLSchema#string